APRIL 21, 2022
LUND, Sweden – Laura Chirica has a broad and extensive experience within life science, diagnostics and biotech industry. Her insights include technology development, company and commercialization strategy, organization development, sales and marketing, business development, stock market introduction, project, and program management. Laura has been responsible for large capital projects, portfolios of products and platforms for production of biologics, building organizational capabilities, and for overall business delivery in both management, executive and board roles.
Throughout her career Laura has been working for large multinationals, medium size and startup companies. During the last 20 years, she has held management positions in GE Healthcare- now “Cytiva”, Dako- now “Agilent Technologies”, Sartorius, EuroDiagnostica- now” Svar Science” and most recently, Immunovia. Laura holds a Bachelor of Science (BSc) degree in Biotechnology, Master of Science degree (MSc) in Food Biotechnology and a Philosophy Doctor degree (PhD) in biochemistry from Umeå University, Sweden.
“We are very pleased that Laura Chirica has accepted the position of new CEO of Cellevate. She has a broad and quite unique experience, from both large-scale commercialization in biologics manufacturing as well as company strategic development from start up to commercial launch which we believe will be very valuable for our company” says Cellevate’s Chairman of the Board, Mats Leifland.
“Laura has demonstrated her ability to building successful organizations and businesses. We are confident that she will be a force in developing and driving Cellevate forward – in a very exciting but also challenging time.” Mats Leifland says further, “I would also like to use this opportunity to sincerely thank Maximilian Ottosson for his years of commitment and hard work and for laying a successful foundation for Cellevate.” Maximilian has decided to step down from his CEO role, but he will continue in the management team as Cellevates´s Chief Operating Officer.
“I have truly enjoyed my time leading Cellevate the last 6+ years but I am very happy to welcome Laura to the Cellevate team as our new CEO. I believe she is the right person to hand over the company to as we enter this new and exciting phase of our journey. In my new role as COO, I will support Laura, the team and the board in implementing our company vision to re-invent bioprocessing from R&D to large scale manufacturing” says Maximilian Ottosson.
“I am very excited about joining such a competent and capable team which has both developed a unique technology and commercialized a range of products for life science research applications. The company’s core nanotechnology, Cellevat3d™, has the potential to revolutionize the manufacturing of biologics due its exceptional surface area, scalability and biomimicry, features that provide a unique fit for cell and gene therapy applications. I am certainly looking forward to developing the company further with a clear industrial ambition to change the future of biomanufacturing and to help bring life-changing biotherapies to patients faster and at a lower cost, “says Laura Chirica who has started the position of CEO of Cellevate,
April 7, 2022.
For more information, please contact:
Chairman of the Board Cellevate
Tel: +46-733 – 37 10 06
Laura Chirica, PhD
Tel.: +46-70-984 90 35
Tel.: +46-73-633 93 90
Cellevate develops and markets products based on a proprietary nanofiber-based platform – the Cellevat3d™ – with the potential to revolutionize upstream bioprocessing from R&D to commercial manufacturing. Our latest product line in development – Cellevat3d™ microcarriers – with a commercial launch planned for 2024, provides extracellular-like environments with exceptional surface areas for adherent cell cultures. Initial results show tremendous potential to increase yields, minimize risk and reduce costs in development and manufacturing.
We offer a range of products based on our versatile and easily functionalized platform for several applications, including next generation cell- and gene therapies.
For more information, please visit www.cellevate.com/news